Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease

Chiara Viviani Anselmi, Carlo Briguori, Roberta Roncarati, Laura Papa, Gabriella Visconti, Amelia Focaccio, Francesca De Micco, Michael V G Latronico, Paolo Pagnotta, Gianluigi Condorelli

Research output: Contribution to journalArticle


Objectives This study sought to assess the usefulness of clopidogrel-pathway genotyping and on-treatment platelet reactivity (OTR) testing in predicting major adverse cardiac events (MACE) in stable coronary artery disease (CAD) patients receiving drug-eluting stents (DES) under dual antiplatelet (clopidogrel plus aspirin) therapy. Background The role of pharmacogenetics and OTR in predicting MACE - death, myocardial infarction, or stent thrombosis - in stable CAD patients scheduled for DES implantation is still debated. Methods Patients with stable CAD treated by DES implantation (n = 1,432) were genotyped with a TaqMan OpenArray (Applied Biosystems, Carlsbad, California) and assessed for OTR with the VerifyNow P2Y12 test (Accumetrics Inc., San Diego, California). Genes tested were ABCB1, CYP1A2, CYP2B6*9, CYP2C8*3, CYP2C9*2, CYP2C19, CYP3A4, CYP3A5*3, P2RY12, and PON1CYP2C19. High OTR was defined as P2Y12 reaction units ≥230. The endpoint at 12-month follow-up was MACE occurring during antiplatelet therapy. Results All groups that were stratified for loss-of-function variants of the cytochrome P450 gene CYP2C19 had significant hazard ratios (HR) for MACE (genotypic HR: 1.41, 95% confidence interval [CI]: 1.06 to 1.89, p = 0.01; allelic HR: 1.56, 95% CI: 2.26 to 1.2, p = 0.01). Variants of other clopidogrel-pathway genes were not significantly associated with MACE. When OTR was assessed, clinical significance was found only in high-risk diabetic (HR: 2.11, 95% CI: 1.29 to 3.45, p <0.001) and chronic kidney disease (HR: 2.03, 95% CI: 1.03 to 4.02, p = 0.04) patients. Conclusions CYP2C19 metabolizer status is an independent predictor of MACE after DES implantation and can be used for prognostication in all stable CAD patients. High OTR, as assessed by the VerifyNow P2Y12 test, is an independent predictor of MACE only for high-risk subsets, that is, patients with diabetes or chronic kidney disease.

Original languageEnglish
Pages (from-to)1166-1175
Number of pages10
JournalJACC: Cardiovascular Interventions
Issue number11
Publication statusPublished - Nov 2013



  • angioplasty
  • clopidogrel
  • genetics
  • negative outcome
  • platelet reactivity
  • predictive test

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this